Novartis Restructure Sees Drug Development And Oncology Chiefs Exit

Aims To Boost R&D And Commercial Performance

 
• By Andrew McConaghie

Tsai and Schaffert out as the Swiss giant looks to maximize returns from its US business, and find more transformational drugs with the help of a new ‘strategy and growth officer’.

Novartis_Building
Novartis aims to save $1bn over the next few years, and find more transformational new medicines from inside and outside its own R&D operations. • Source: Getty Images

More from Anticancer

More from Therapy Areas